Germany · Delayed Price · Currency is EUR Celyad Oncology Statistics
Total Valuation
Celyad Oncology has a market cap or net worth of EUR 8.71 million. The enterprise value is 8.75 million.
| Market Cap | 8.71M |
| Enterprise Value | 8.75M |
Important Dates
The next estimated earnings date is Thursday, September 24, 2026.
| Earnings Date | Sep 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 44.76M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +17.90% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.48% |
| Owned by Institutions (%) | 0.04% |
| Float | 17.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 46.81 |
| PB Ratio | -2.81 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.36 |
| EV / Sales | 47.03 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.66
| Current Ratio | 0.66 |
| Quick Ratio | 0.42 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -64.40 |
Financial Efficiency
Return on equity (ROE) is -7,871.95% and return on invested capital (ROIC) is -405.75%.
| Return on Equity (ROE) | -7,871.95% |
| Return on Assets (ROA) | -43.41% |
| Return on Invested Capital (ROIC) | -405.75% |
| Return on Capital Employed (ROCE) | -325.42% |
| Revenue Per Employee | 10,333 |
| Profits Per Employee | -358,611 |
| Employee Count | 19 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.76% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -70.76% |
| 50-Day Moving Average | 0.21 |
| 200-Day Moving Average | 0.35 |
| Relative Strength Index (RSI) | 47.63 |
| Average Volume (20 Days) | 198 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Celyad Oncology had revenue of EUR 186,000 and -6.46 million in losses. Loss per share was -0.16.
| Revenue | 186,000 |
| Gross Profit | 175,000 |
| Operating Income | -6.44M |
| Pretax Income | -6.46M |
| Net Income | -6.46M |
| EBITDA | -6.28M |
| EBIT | -6.44M |
| Loss Per Share | -0.16 |
Balance Sheet
The company has 790,000 in cash and 831,000 in debt, giving a net cash position of -41,000.
| Cash & Cash Equivalents | 790,000 |
| Total Debt | 831,000 |
| Net Cash | -41,000 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -3.10M |
| Book Value Per Share | -0.07 |
| Working Capital | -1.26M |
Cash Flow
| Operating Cash Flow | -6.12M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 94.09% |
| Operating Margin | -3,462.37% |
| Pretax Margin | -3,470.43% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Celyad Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.90% |
| Shareholder Yield | -17.90% |
| Earnings Yield | -74.14% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Celyad Oncology has an Altman Z-Score of -93.11 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -93.11 |
| Piotroski F-Score | 3 |